'Rejuvenation' protects neurons in mouse models of Parkinson's disease

Nature

Volumn 447, Issue 7148, 2007, Pages 1081-1086

  Chan, C Savio ^a   Guzman, Jaime N ^a   Ilijic, Ema ^a   Mercer, Jeff N ^a   Rick, Caroline ^a,c   Tkatch, Tatiana ^a   Meredith, Gloria E ^b   Surmeier, D James ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; ISRADIPINE;

BRAIN; DISEASE; DISEASE SEVERITY; HORMONE; MODEL; NERVOUS SYSTEM DISORDER;

ADULTHOOD; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; IN VIVO STUDY; JUVENILE; LATENT PERIOD; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PACEMAKER; PARKINSON DISEASE; PRIORITY JOURNAL; REJUVENATION; RHYTHM; STRESS; SUBSTANTIA NIGRA;

EID: 34347359673     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05865     Document Type: Article

References (66)

1. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134 (2004).
2. Hornykiewicz, O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925-964 (1966).
3. Riederer, P. & Wuketich, S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38, 277-301 (1976).
4. Abou-Sleiman, P. M., Muqit, M. M. & Wood, N. W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Rev. Neurosci. 7, 207-219 (2006).
5. Zhang, L. et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis. Hum. Mol. Genet. 14, 2063-2073 (2005).
6. Kwong, J. Q., Beal, M. F. & Manfredi, G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 97, 1659-1675 (2006).
7. Bender, A. et al. High levels of mitochondrial DNA deletions in substantia nigraneurons in aging and Parkinson disease. Nature Genet. 38, 515-517 (2006).
8. Kraytsberg, Y. et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nature Genet. 38, 518-520 (2006).
9. Swerdlow, R. H. et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40, 663-671 (1996).
10. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822 (2003).
11. Greenamyre, J. T. & Hastings, T. G. Biomedicine. Parkinson's - divergent causes, convergent mechanisms. Science 304, 1120-1122 (2004).
12. Zecca, L., Zucca, F. A., Wilms, H. & Sulzer, D. Neuromelanin of the substantia nigra: A neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26, 578-580 (2003).
13. Michel, P. P. & Hefti, F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26, 428-435 (1990).
14. Kish, S. J., Shannak, K. & Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880 (1988).
15. Hasbani, D. M., Perez, F. A., Palmiter, R. D. & O'Malley, K. L. Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity in vivo. J. Neurosci. 25, 9428-9433 (2005).
16. Fahn, S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 252 (Suppl. 4), IV37-IV42 (2005).
17. Mercuri, N. B. et al. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol. 113, 831-838 (1994).
18. 2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. (Lond.) 466, 727-747 (1993).
19. Shepard, P. D. & Stump, D. Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons. Brain Res. 817, 104-109 (1999).
20. 1 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J. Neurosci. 21, 5944-5951 (2001).
21. 2+ channels is dependent on a Shank-binding domain. J. Neurosci. 25, 1050-1062 (2005).
22. 2+ channels activating at negative voltages. J. Biol. Chem. 276, 22100-22106 (2001).
23. 1D) calcium channel subunit from an insulin-secreting cell line. Mol. Endocrinol. 15, 1211-1221 (2001).
24. Surmeier, D. J., Mercer, J. N. & Chan, C. S. Autonomous pacemakers in the basal ganglia: Who needs excitatory synapses anyway? Curr. Opin. Neurobiol. 15, 312-318 (2005).
25. Zolles, G. et al. Pacemaking by HCN channels requires interaction with phosphoinositides. Neuron 52, 1027-1036 (2006).
26. h channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci. 22, 1290-1302 (2002).
27. Beal, M. F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44, S110-S114 (1998).
28. Coyle, J. T. & Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695 (1993).
29. 2+ and neurodegenerative disease. Eur. J. Pharmacol. 447, 177-188 (2002).
30. Verkhratsky, A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol. Rev. 85, 201-279 (2005).
31. Dauer, W. & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
32. Phinney, A. L. et al. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Relat. Disord. 12, 228-238 (2006).
33. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301-1306 (2000).
34. Jiang, Q., Yan, Z. & Feng, J. Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism. J. Neurosci. 26, 4318-4328 (2006).
35. Bywood, P. T. & Johnson, S. M. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices. Exp. Neurol. 179, 47-59 (2003).
36. Przedborski, S. & Vila, M. The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. 991, 189-198 (2003).
37. Petroske, E., Meredith, G. E., Callen, S., Totterdell, S. & Lau, Y. S. Mouse model of Parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106, 589-601 (2001).
38. Wilson, C. J. & Callaway, J. C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol. 83, 3084-3100 (2000).
39. Orrenius, S., Zhivotovsky, B. & Nicotera, P. Regulation of cell death: The calcium-apoptosis link. Nature Rev. Mol. Cell Biol. 4, 552-565 (2003).
40. Kazuno, A. A. et al. Identification of mitochondrial DNA polymorphisms that alter mitochondrial matrix pH and intracellular calcium dynamics. PLoS Genet. 2, e128 (2006).
41. Yamada, T., McGeer, P. L., Baimbridge, K. G. & McGeer, E. G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526, 303-307 (1990).
42. Ai, Y. et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects. J. Comp. Neurol. 461, 250-261 (2003).
43. Coleman, M. Axon degeneration mechanisms: Commonality amid diversity. Nature Rev. Neurosci. 6, 889-898 (2005).
44. Kupsch, A. et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 6, 621-625 (1995).
45. Kupsch, A. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 741, 185-196 (1996).
46. Grossman, E., Messerli, F. H., Oren, S., Nunez, B. & Garavaglia, G. E. Cardiovascular effects of isradipine in essential hypertension. Am. J. Cardiol. 68, 65-70 (1991).
47. Johnson, B. A., Devous, M. D. Sr, Ruiz, P. & Ait-Daoud, N. Treatment advances for cocaine-induced ischemic stroke: Focus on dihydropyridine-class calcium channel antagonists. Am. J. Psychiatry 158, 1191-1198 (2001).
48. Rodnitzky, R. L. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 57, 845-849 (1999).
49. Chan, C. S., Shigemoto, R., Mercer, J. N. & Surmeier, D. J. HCN2 and HCN1 channels govern the regularity of autonomous pacemaking and synaptic resetting in globus pallidus neurons. J. Neurosci. 24, 9921-9932 (2004).
50. Hows, M. E. et al. High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. J. Neurosci. Methods 137, 221-226 (2004).
51. 2+ channels. Cell 102, 89-97 (2000).
52. Nelson, E. L., Liang, C. L., Sinton, C. M. & German, D. C. Midbrain dopaminergic neurons in the mouse: Computer-assisted mapping. J. Comp. Neurol. 369, 361-371 (1996).
53. Paxinos, G. & Franklin, K. B. J. The Mouse Brain in Stereotaxic Coordinates (Elsevier Academic, San Diego, 2004).
54. Grace, A. A. & Bunney, B. S. The control of firing pattern in nigral dopamine neurons: Single spike firing. J. Neurosci. 4, 2866-2876 (1984).
55. Grace, A. A. & Onn, S. P. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J. Neurosci. 9, 3463-3481 (1989).
56. Yung, W. H., Hausser, M. A. & Jack, J. J. Electrophysiology of dopaminergic and non-dopaminergic neurones of the guinea-pig substantia nigra pars compacta in vitro. J. Physiol. (Lond.) 436, 643-667 (1991).
57. + channels reduces autonomous activity in striatal cholinergic interneurons. J. Neurosci. 24, 10289-10301 (2004).
58. Tkatch, T., Baranauskas, G. & Surmeier, D. J. Basal forebrain neurons adjacent to the globus pallidus co-express GABAergic and cholinergic marker mRNAs. Neuroreport 9, 1935-1939 (1998).
59. Song, W. J. et al. Somatodendritic depolarization-activated potassium currents in rat neostriatal cholinergic interneurons are predominantly of the A type and attributable to coexpression of Kv4.2 and Kv4.1 subunits. J. Neurosci. 18, 3124-3137 (1998).
60. Surmeier, D. J., Song, W. J. & Yan, Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16, 6579-6591 (1996).
61. Mandir, A. S. et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl Acad. Sci. USA 96, 5774-5779 (1999).
62. Meredith, G. E. & Kang, U. J. Behavioral models of Parkinson's disease in rodents: A new look at an old problem. Mov. Disord. 21, 1595-1606 (2006).
63. Hines, M. L. & Carnevale, N. T. NEURON: A tool for neuroscientists. Neuroscientist 7, 123-135 (2001).
64. Migliore, M., Cook, E. P., Jaffe, D. B., Turner, D. A. & Johnston, D. Computer simulations of morphologically reconstructed CA3 hippocampal neurons. J. Neurophysiol. 73, 1157-1168 (1995).
65. Wang, J., Chen, S., Nolan, M. F. & Siegelbaum, S. A. Activity-dependent regulation of HCN pacemaker channels by cyclic AMP: Signaling through dynamic allosteric coupling. Neuron 36, 451-461 (2002).
66. Shen, W., Hamilton, S. E., Nathanson, N. M. & Surmeier, D. J. Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J. Neurosci. 25, 7449-7458 (2005).